Androgen Deficiency in Endocrine Practice: Improving Patient Outcomes through Screening and Treatment

San Diego, CA US
March 7, 2015

Saturday, March 7, 2015 | 5:45 – 8:00 AM PST
Hilton San Diego Bayfront Hotel, Sapphire Ballroom B

This course is a live CME-certified ancillary symposium presented at ENDO 2015, the Endocrine Society's 97th Annual Meeting and Expo, held in San Deigo, California, March 5–8, 2015. ENDO 2015 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC). There is no cost to attend, and all ENDO 2015 attendees are welcome; however, seating is limited and advance registration is recommended. You must be registered for ENDO 2015 to attend an ENDO 2015 ancillary  symposium.

This activity is supported by an educational grant from AbbVie Inc. 


Welcome and Introduction
Program Director: Frances J. Hayes, MD – Massachusetts General Hospital 

The Role of Testosterone and Pathophysiology of Androgen Deficiency
Thomas Hugh Jones, BSC, FRCP, MD – University of Sheffield (UK)

Screening and Diagnosing Androgen Deficiency
Andrea Coviello, MD – Boston University 

Updates in Testosterone Replacement Therapy
Shehzad Basaria, MD – Brigham & Women’s Hospital

Clinical Case Roundtable and Discussion

Target Audience

This program should be of substantial interest to: endocrinologists and endocrine fellows with additional interest from primary care and internal medicine physicians, physician’s assistants, nurse practitioners and other healthcare professionals caring for individuals with or at risk of developing androgen deficiency.

Learning Objectives

Upon completion of this educational activity, participants will be better able to:

  • Discuss of physiological roles of testosterone and pathophysiology of androgen deficiency in men
  • Identify signs and symptoms of androgen deficiency taking into consideration patient risk factors
  • Recognize the association of androgen deficiency with comorbid conditions and screen individuals appropriately
  • Select among available testosterone replacement therapies to individualize patient care

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Men’s Health
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation
Course opens: 
Course expires: 
Event starts: 
03/07/2015 - 5:45am
Event ends: 
03/07/2015 - 8:00am
Hilton San Diego Bayfront
1 Park Boulevard
Sapphire Ballroom B
San Diego, CA 92101
United States

Frances J. Hayes, MD – Program Director
Clinical Director, Endocrine Division
Massachusetts General Hospital
Boston, Massachusetts

Thomas Hugh Jones, BSC, FRCP, MD
Consultant Physician & Endocrinologist
Hon. Professor of Andrology
Robert Hague Center for Diabetes and Endocrinology
Barnsley Hospital NHS Foundation Trust
Department of Human Metabolism
University of Sheffield
Sheffield, United Kingdom

Andrea Coviello, MD, MSE, FACE
Section of Preventive Medicine and Epidemiology
Section of Endocrine, Diabetes and Nutrition
Boston University School of Medicine
Boston, Massachusetts

Shehzad Basaria, MD
Medical Director, Section on Men’s Health, Aging & Metabolism
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships: Shehzad Basaria, MD: Consultant, Eli Lilly & Co., Endo Pharmaceuticals; Principal Investigator, Abbott Laboratories

The following faculty reported no relevant financial relationships: Andrea Coviello, MD, MSE, FACE; Frances J. Hayes, MD; Thomas Hugh Jones, BSC, FRCP, MD

The following SPC member who planned and/or reviewed content for this activity reported no relevant financial relationships: Michael Irwig, MD

The following SPC Committee members reported relevant financial relationships:
Sarah Berga, MD: Advisory Board Member, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Irl B. Hirsch, MD: Consultant, Abbott Laboratories, Becton Dickinson, Roche Diagnostics; Grant Support, Halozyme, Sanofi
E. Michael Lewiecki, MD: Consultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck;
Anton Luger, MD: Advisory Board Member, Investigator and Speaker, Novo Nordisk; Advisory Board Member and Speaker, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Ipsen, Merck, Merck, Sharp & Dome, Novartis, Pfizer, Reckitt Benkiser, Takeda; Investigator, Roche
Guillermo E. Umpierrez, MD, CDE: Advisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron
Amy Rothberg, MD: Consultant, Novo Nordisk; Speaker, Takeda Pharmaceuticals
Andrea L. Utz, MD, PhD: Investigator, Corcept, Ipsen

The following SPC members reported no relevant financial relationships: Jeffrey Boord, MD, MPH; Larry Fox, MD; and Connie B. Newman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation